The new UK RSV maternal vaccination programme and ethnic disparities in uptake in a diverse urban population: A Retrospective Study
This retrospective study of a diverse UK urban population reveals moderate overall uptake (51%) of the new antenatal RSV vaccination programme but highlights significant ethnic disparities, with notably lower acceptance among Pakistani women compared to White British and Bangladeshi groups, underscoring the need to address these inequalities to maximize public health impact.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, a common virus called respiratory syncytial virus, or RSV, sweeps through communities and causes severe breathing trouble for babies under six months old. This virus is the primary reason infants are rushed to the hospital with inflamed airways and difficulty breathing. For a long time, doctors could only treat the symptoms once a baby became sick, but a new approach has recently changed the strategy. Instead of waiting for the virus to strike, health officials in the United Kingdom began recommending that pregnant women receive a vaccine during their pregnancy. The goal is for the mother's body to build up defenses and pass them directly to the unborn baby through the placenta, giving the infant a shield of protection right from birth. This method relies on the natural connection between mother and child to stop the virus before it can cause harm.
In the autumn of 2024, this new vaccination program launched across the National Health Service, inviting expectant mothers to get the shot starting at twenty-eight weeks of pregnancy. A team of researchers at two hospitals in the UK decided to look closely at how this program was working in its first few months. They wanted to see if the vaccine was reaching all the people who needed it, or if certain groups of people were missing out. The team examined records from nearly six thousand births that occurred between September 2024 and April 2025. They tracked which mothers received the vaccine and looked at the ethnic background of the families to see if there were patterns in who said yes and who said no.
The results showed that just over half of the eligible mothers, about fifty-one percent, chose to get the vaccine. While this number indicates a decent start for a brand-new program, the researchers found that the decision to get vaccinated was not the same for everyone. The uptake varied significantly depending on a family's ethnic background. Mothers who identified as White British had the highest rate of vaccination, with sixty-two percent receiving the shot. Women of Bangladeshi heritage also showed strong participation at fifty-nine percent. However, the numbers dropped sharply for other groups. Only thirty percent of Pakistani women received the vaccine, and rates were similarly low for mothers identifying as Black or of mixed ethnicity, both sitting at thirty-eight percent. These differences highlight that while the vaccine is available to everyone, it is not yet reaching every community equally.
The study also took a brief look at what happened to the babies after they were born. The researchers reviewed the records of sixty-seven infants who were admitted to the hospital with serious breathing infections. Among these sick babies, fifteen tested positive for RSV. Only one of those fifteen had a mother who had received the vaccine. In contrast, among the babies who were sick but did not have RSV, fourteen had mothers who had been vaccinated. This pattern suggests that the vaccine might be helping to protect babies from the worst outcomes of the virus, though the number of cases was too small to prove this with absolute certainty. The researchers noted that their study was not designed to calculate exactly how well the vaccine worked, but the early signs are consistent with what clinical trials have shown.
The authors of the study point out that these disparities in vaccination rates are a cause for concern. If the vaccine is not reaching the communities that need it most, it could widen existing gaps in health rather than closing them. Previous studies have shown that infants from some minority ethnic backgrounds in the UK already face a heavier burden of illness from RSV. If the new vaccine is not distributed evenly, it risks leaving the most vulnerable children without protection. The researchers suggest that the lower rates among certain groups may be due to barriers such as language difficulties, a lack of trust in the medical system, or simply not having enough clear information about the new vaccine. They emphasize that as the program continues, health workers will need to focus on reaching out to these specific communities with culturally sensitive education to ensure every baby has a fair chance at staying healthy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.